Mesoblast Ltd

MESO

Healthcare|Biotechnology|Australia

$15.46

+0.60 (+4.04%)

Tangible Book

$0.07

Upcoming Data Readouts (1)

Jul 2027

Est. completion

P3Degenerative Disc Disease

Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain